- Home
- VCYT vs ZLAB Comparison
VCYT vs ZLAB Comparison
Compare VCYT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCYT | ZLAB |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VCYT | ZLAB |
|---|---|---|
| Price | $49.15 | $21.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $59.73 | $33.48 |
| AVG Volume (30 Days) | ★ 1.1M | 992.1K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 164.52 | 38.46 |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $14.82 | N/A |
| Revenue Next Year | $11.16 | $26.68 |
| P/E Ratio | $76.30 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $29.46 | $15.96 |
| 52 Week High | $60.91 | $27.50 |
Technical Indicators
Market Signals| Indicator | VCYT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 39.35 |
| Support Level | $39.85 | $17.16 |
| Resistance Level | $49.46 | $26.64 |
| Average True Range (ATR) | 2.30 | 1.13 |
| MACD | 0.54 | -0.19 |
| Stochastic Oscillator | 70.07 | 8.50 |
Price Performance
Historical ComparisonAbout VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.